About us
- >
- About us >
- Information >
- Announcement
Announcement
-
2023-07-25Our invention patent for "Compound Activating AMPK and its Use" for the treatment of prediabetes and type 2 diabetes has been approved in Ca
-
2023-06-26ENERGI-F703 diabetic foot ulcer topical gel has received approval from the Taiwan Food and Drug Administration (TFDA) to initiate Phase III clinical t
-
2023-06-13Announcement: Energenesis Biomedical has signed a Memorandum of Understanding (MOU) with Healiva SA, a company ba
sed in Switzerland, to establish a -
2023-06-09Announcement: Energenesis Biomedical's stock is going to be delisted from the emerging stock market, and will be transferring to the Taiwan Stock
-
2023-05-31The Phase III clinical trial of ENERGI-F703 diabetic foot ulcer topical gel has officially commenced, with the enrollment it's first patient.
-
2023-02-10Patent for "Compound Activating AMPK and Uses Thereof" aimed at treating inflammatory diseases has been approved in Canada.
-
2023-01-09ENERGI-F703EB has received a certification letter from the Office of Orphan Products Development (OOPD) of the US Food and Drug Administration (FDA),
-
2022-12-26ENERGI-F703EB has received a certification letter from the Office of Orphan Products Development (OOPD) of the US Food and Drug Administration (FDA),
-
2022-11-14In response to Energenesis Biomedical's application for listing, it is necessary for us to engage a certified public accountant to issue an inter
-
2022-10-28We has signed a new drug formulation development contract with CBC Biotechnological & Pharmaceutical Co., Ltd.